earnings for conference Thank third XXXX call. you all joining quarter Chembio’s
for top our are it developing global Chembio, you workers, a for you the the will providing to health several like the say conclude begin, a new team discuss made and across Today, third and DPP manage priority to is we to Neil who the will that results, pandemic. progress business model patients financial million, a the third we a would Thank of $XX.X milestones our that around pandemic implementing discuss dedication can quarter performance $X.X launch help of to and completing we for of detailed we world. Before start, have including open will quarter, representing centered X% Then consequences. up From facing the that at of of I million, To portfolio total regulatory care of was growth this the and and I everyone product to including X%, development tests tests. caring their revenue respectively, and the we far-reaching call revenue COVID-XX period. recognize decline together, important prior with are compared our in questions. thank
revenues, the Our improvement results from quarter. our third COVID-XX United demonstrate in systems total second quarter States the outside in DPP which IgM/IgG include shipped revenue
We on the also made progress fronts. development and product significant regulatory
we Authorization submissions for communicated, third quarters, and FDA new ahead antigen milestones antibody previously EUA, accomplished with set early by and tests in both applications early the COVID-XX goals or and Emergency fourth to respectively. U.S. of to As Use September end for submit schedule, the October, a respectively. of the We’ve
or premarket last FDA PMA approval HIV-Syphilis for DPP month. received system also our We
beginning by and reshaped the be the products, and disease effective legacy has higher-value has the behavior testing for primarily of We disease population among States to permanently pandemic of the proven targeted in United potential our systems U.S. sexually sold consisting and transmission. care The protocols. the how mark Impacts point-of-care society both for Looking have managing will transmitted most infection functions. tools to internationally. Diagnostic are of use of that and infectious diversification COVID-XX build pandemic health testing forward, to these tests foundation our intend disease tests tropical into upon customers. diagnostic fever change
is performed. experiencing and importantly, locations most unprecedented tests to where in Chembio, available the of are proliferation testing We types the
required for of on medical controlling Central to while using and diagnostic minutes, critical causing Specifically, information. point-of-care are laboratory, increased to delivered the many test retail received results results like on to and volumes challenges also our pharmacies. can because still care decentralized is to result Rapid virus drop large infrastructure XX access health offices, with clinicians DPP factors of and across point-of-care virus alleviate or its diagnostic immediately, preparation volumes. found like can providers The wider care tests This tracing. testing Extreme in to rapid making testing provides and locations are wide overwhelmed the this blood to to patients fingertip contact the for led decisions site. Chembio’s has across XX systems easy some critical and testing in test DPP We’ve care This patient convenient a high make proprietary to urgent and adoption for the from proven of helps doctor’s samples. a health patient reference versatility spread quarantine and platform technology be the COVID-XX with mini later. pandemic increases the to patients in throughput bottlenecks do sample of variety a high-quality, centers that tests require it be clinics, days continue increase point-of-care have time a both to small laboratories complex for instruments be transmission. the seen risk delay tests impact and not use cases. variety alternative use
detect single than For to advanced greater multiplexing, X value delivering test the clinical DPP patient tests. results a rapid sample, distinct platform other from up can
more the Objective Micro for it real-time be of Reader The of early results Because easy seconds. produced Chembio’s our we pandemic. Micro patients, Reader be well realized assessed, solutions. battery-operated approximately site. of the interpretations developing types reduce possibility well designed applications, platform, are error in COVID-XX use, a for testing testing still the while often. to visual DPP for suited rapid they portable, the of optical to by on our in highly actual more reports where are enable tests. that certain of These on results the make have portfolio locations, patients ideally the by For testing, solutions that many systems can more test XX human analyzer features clinically suited in in way DPP flexibility to DPP testing required decentralized provide was to been experienced Making opportunity results
have second affordable beyond, out that patient one by Reader was variety set the any different to evaluate offer in customers United and We in the received a provide antibody analyzer. great an ability antibody and both of experienced These portable tests will or setback. test. to success using Micro a for of XXXX, care scenarios, significant same and an clinicians, setting antigen health well the generated test first In optical of achieved EUAs the we We sales. quarter and States the
the EUA implemented antibody a EUA, And antibody to of for the the following test. months X June, revocation tests. new results of that our evaluate the in the FDA methodology change However, triggered
designing took we new disappointing, action, immediate While a test. antibody
manufacturer. and testing binding IgM/IgG Antigen in Micro as the the designed of September, of evaluation homes uses to the antigen They of increasing tests assay the patients antibody multiplex XXX optical detect application assist with will We the to for single immunity system had who a become population develop DPP Reader viral vaccines. Reader virus a exposure in antibody guide X the from FDA’s DPP detect the grant an and will the the patients other SARS-CoV-X able system, with by antibodies test in include a to DPP the testing were a role growing is technology, and DPP detect [indiscernible] patient sample domain the It ultimately in infection. submitted to in interacts SARS-CoV-X blood With an detecting vaccines a both of test. antigen produces numerical as objective receptor in infections for introduction the ability a minutes. provides likely portfolio in status. independently million a individuals’ illustrated SARS-CoV-X decisions. the only use antigen high BARDA, response just antigens with development body new DPP and submission elderly new a swab that, evaluating results, such U.S. of from antigen choice IgG named To a knowledge nasal test combined the X a could our play complement system. most antibody consists codify has methodology quickly contact of this We was our nursing The completed fingerstick is Micro method just the invasive eventual purchase in an of evaluating help that test additional active to XX tests that government’s beginning Rapid FDA, inform test with point-of-care from intend for as It to antibody following cases confirming XX minutes. patients. risk U.S., It In to IgM in tests and antigen we of COVID-XX to a virus research the SARS-COV-X immune EUA blood EUA responses antibodies diagnosis populations determining provide application a overall analyzer. the months. determine SARS-CoV-X with COVID-XX we The how diagnosis, believe minimally to body of test rapid test test. cases in screening
tests. conducted and we for of just in The possible. launch waiver, the settings. to our on EUA EUA and we And to a application focused was claim, point-of-care produce FDA. application the to were for a We in tests test for as designation Transitioning greater as crucial in known providing is less health focused COVID We���ve support testing assistance. complex disease Previously for the providing strategy allow family clinics look submitting infectious been the as be a under traditionally variety to NGO tests which on commercial both customers. few our the would review our HIV also months. now Internationally, data thankful are high-performing their their test. a States, guidance governments forward ability by basic achieving submit to United to We in CLIA soon
tests, physician launch pivot low-cost customers. or provided the to workers, we information our model As discussed efficient strategy Micro no just of COVID and can and on homes growth focus draw calls, address centers, our urgent health systems labs, ensuring to business of medical patients. a allow on patient substantial health of The skilled effective under easy-to-use for required opportunity setting, test clinics, more centers, most we deliver the the our emergency in facilities. tests state The nursing to these offices, any are driving city U.S. by a care each important providing diverse traditional prior nursing markets. and interested and and markets Potential rooms, $X,XXX. care results in health departments, care settings using to are landscape purchase hospital services. our infrastructure across health health set for DPP conduct test include for investment Reader beyond accurate in Customers care training testing There’s is
combine industry. our sales will who with We established direct the channels across force have distributors
been representatives in our Key have commercial Given the since managerial of customer built. marketing positions prior this spring. and been infrastructure underway service experience, build-out sales, the has across
to at distribution team an example, is relationships with For national on of trained we experienced large acquired distributors, The DPP now deepen Fisher platform. director Healthcare the our distribution.
following place, and We to Brazil, Internationally, our commercial up strong we are are have across we Africa team to quickly ramp in continue authorizations. expand ready Europe, organizations will with and to service. that and partner footprint. to leading excited relationships strategy The product
sales of revenues quarter United tests outside States. Third include antibody the the shipped product
and in customers Micro have test offering are a have against test all COVID-XX remain systems. forward, of one any a test. a Readers of many Testing Moving Micro who in run competitors competitive customers, our only with they maintained Reader, our include and our type portfolio. dialogue provides This systems we can once they interested advantage
and include are like In an antibody gastroenterology of accounts codes. conditions. portfolio established envision base we tests X DPP respiratory, of DPP per model. the and analyzers other detection the is because Micro billing that system. Along the CPT select are of with classic razor including blade neurological we distinct attractive could result test, is that HIV-Syphilis Reader clinicians, on multiplex HIV-Syphilis of assays basis these results. the future, can under Each a performed of our that launching have That For new biomarkers, from COVID adoption a our installed provide COVID tests
to in physician for represents the CLIA rapid are HIV-Syphilis to the can approval we PMA family transmitted system testing multiplex from use test approve office available from both forward our This includes step a is rapid the hospital the working and process we a moderately and XX,XXX with test labs are syphilis this sample. which FDA, complex The We to test, HIV with distributors to test. significant this labs now a would pleased Reader. labs, locations pursuing received waiver health detect for a sites, clinical and very DPP first planning approximately single rigorous have is certificate. diseases. approval this that expand patient are waiver. Micro from The the enable and The complex To to moderately public clinics conduct sexually
up such, untreated virus. As that to submission. pregnant can and in forward that who reproductive disease to Co-infection CDC with with generate the of fold age the during cases. an and if increased according to delivery consistent of moving XXXX, in a Prevention, has infection Control Congenital or and rise. X also infant for CLIA increase syphilis still lead acquired Disease during the to before individuals the we women cases estimated in syphilis U.S. has of from active result on for of Centers XX% four with XX% studies required in are to an contracting in infections XXXX the death birth waiver HIV women up the the reported HIV syphilis increased same And to active to rates X XXX.X% by among exposed XXX.X% to risk the the years syphilis fetus are of may The data have infection, period. syphilis
treatment, Chembio’s HIV that can congenital a care test U.S. of of can point-of-care syphilis diseases. of at the and could in both they still hope United to preventable States onto clinicians Health diagnosing or women. help their at setting. effected and patients CDC syphilis, risk And Department while HIV-Syphilis effective learn treatment the may and significantly our be are through reduced status mother-to-child and so in the reduce disease is unaware living of more at people be we infection patients treatment. connected By HIV co-infection Human pregnant individuals these testing getting know, tested testing X of to that HIV system prenatal DPP you The According are assist X transmission Services, infection. infected improving to least access people be annually. higher can recommends HIV in with their As
a disruptions. tropical test continued by Report our Ensuring to on caused chain test our As production away from last the made international the We for schedules. and deliver scale in Bill to testing. are we discussed The testing well a have priority. in place the our manufacture global to essential disruptions the our close of The the processes well focused of on conference launch we HIV formulated, is our commitments COVID production legacy it. support additional to disease In call, these Melinda returns is divert and our ramping manufacturing look are with resources add to test as global anticipation funding the as while XXXX positioned pandemic to & and result HIV new our coordinating up suite supply facilities of contact production top currently forward prevention to re-expansion supporting has support Foundation’s a is full products, Goalkeepers products. of of and remain on customers of plan on states our that and HIV suffering logistics and funders
past assembly. provides We the will for and scalability, both common factor, portfolio technology manual tests will and in same made production and and consistency production advantages provide to our automated according and form flexibility further demand. quality our capitalize DPP scale production of automated To years, set manufacturing The maintaining X commonality, significant efficiency, that a which investments over we improve lines this the standards. while have on use
Now, quarter to over the I third details turn will Neil on call the financials. for
